Back
Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference.
Journal article

Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference.

  • Mehta N Department of Medicine, University of California San Francisco, San Francisco, CA.
  • Bhangui P Institute of Liver Transplantation and Regenerative Medicine, Medanta, The Medicity, Gurgaon, India.
  • Yao FY Department of Medicine, University of California San Francisco, San Francisco, CA.
  • Mazzaferro V Department of Surgery, GI Surgery and Liver Transplantation, Istituto Nazionale Tumori, Milan, Italy.
  • Toso C Division of Abdominal Surgery, University Hospitals of Geneva, Geneva, Switzerland.
  • Akamatsu N Department of Surgery, The University of Tokyo, Tokyo, Japan.
  • Durand F Service d'Hépatologie & Réanimation Hépatodigestive, Université Paris VII Hôpital Beaujon, Paris, France.
  • Ijzermans J Department of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Polak W Department of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Zheng S Department of Surgery, First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Roberts JP Department of Surgery, University of California San Francisco, San Francisco, CA.
  • Sapisochin G Multi-Organ Transplant and HPB Surgical Oncology, Toronto General Hospital, University of Toronto, Toronto, Canada.
  • Hibi T Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan.
  • Kwan NM Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Ghobrial M J C Walter Jr Transplant Center, Sherrie and Alan Conover Center for Liver Disease and Transplantation, Weill Cornell Medical College, Houston Methodist Hospital and Research Institute, Houston, TX.
  • Soin A Institute of Liver Transplantation and Regenerative Medicine, Medanta, The Medicity, Gurgaon, India.
Show more…
  • 2020-03-29
Published in:
  • Transplantation. - 2020
Carcinoma, Hepatocellular
Consensus
Consensus Development Conferences as Topic
Donor Selection
Europe
Humans
Liver Neoplasms
Liver Transplantation
Living Donors
Medical Oncology
Patient Safety
Patient Selection
Practice Guidelines as Topic
Societies, Medical
United States
Waiting Lists
English Liver transplantation (LT) offers excellent long-term outcome for certain patients with hepatocellular carcinoma (HCC), with a push to not simply rely on tumor size and number. Selection criteria should also consider tumor biology (including alpha-fetoprotein), probability of waitlist and post-LT survival (ie, transplant benefit), organ availability, and waitlist composition. These criteria may be expanded for live donor LT (LDLT) compared to deceased donor LT though this should not adversely affect the double equipoise in LDLT, namely ensuring both acceptable recipient outcomes and donor safety. HCC patients with compensated liver disease and minimal tumor burden have low urgency for LT, especially after local-regional therapy with complete response, and do not appear to derive the same benefit from LT as other waitlist candidates. These guidelines were developed to assist in selecting appropriate HCC patients for both deceased donor LT and LDLT.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/70661
Statistics
Document views: 107 File downloads: